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Abstract
The benefit of albumin administration in the critically ill patient is unproven. Epidemiological
evidence suggests that there is an increase in death among patients with burns,
hypoalbuminaemia, and hypotension treated with human albumin solution (HAS). In critical
illness, hypoalbuminaemia is a result of transcapillary leak, decreased synthesis, large
volume body fluid losses and dilution caused by fluid resuscitation. When treating patients
with hypoalbuminaemia, efforts must be centred around correction of the underlying disorder
rather than reversal of hypoalbuminaemia. Problems with using albumin arise because it is an
expensive blood product, and can result in systemic changes that include cardiovascular,
haematological, renal, pulmonary, and immunological effects.
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Introduction
Any benefit for the use of albumin in the adult, critically ill
patient is unproven. A low serum albumin concentration in
critical illness is known to be associated with a poor
outcome [1–4], but correcting hypoalbuminaemia has no
impact on outcome in the critically ill. There is epidemiologi-
cal evidence to suggest that there is an increase in death
among patients who are treated with HAS for burns, hypoal-
buminaemia and hypotension [5] by up to 6%. The pub-
lished evidence does not support the use of albumin rather
than other agents for volume replacement. We have not
used HAS in 98% of our critically ill patients, because of its
lack of efficacy and high costs. We believe that there is no
role for routine use of albumin in the critically ill patient.
Role of albumin in critical illness
Some of the functions of albumin include the following:
transport; volume expansion and maintenance of colloid
oncotic pressure; and scavenging of free radicals.
Unlike synthetic colloids albumin binds reversibly with
drugs, hormones, bilirubin and metal ions, among other
substances, and so affects their metabolism in the criti-
cally ill patient with hypoalbuminaemia [6,7]. Calcium also
binds to albumin. Administration of albumin has been
shown to result in a decrease in ionic calcium, which
could result in myocardial depression [8].
In the intact vascular compartment, HAS has, in common
with other colloids, the potential to produce significant
volume expansion and has a half-life of 16 h. Serum
albumin provides up to 65–75% of the normal colloid
oncotic pressure, with globulins and fibrinogen accounting
for most of the rest [9–11]. In disease the serum concen-
tration of albumin correlates poorly with colloid oncotic
pressure [12]. The concentration of albumin decreases,
often dramatically, from early in the course of a critical
illness. It does not increase again until the recovery phase
of the illness.Critical Care    Vol 4 No 3 Pulimood and Park
We retrospectively studied the changes in serum albumin
and oncotic pressure between survivors and nonsurvivors of
prolonged critical illness [13]. The oncotic pressure varied
little between or within either group of patients. There was
no relationship between death and oncotic pressure.
Albumin has been shown [14] to be scavenger of free rad-
icals, but this function has not been shown to be of rele-
vance in clinical studies in humans with critical illness.
Causes of hypoalbuminaemia in critical illness
Hypoalbuminaemia reflects morbidity, and predicts mortal-
ity and duration of intensive care unit stay in critically ill
patients [1]. Increasing a low serum concentration of
albumin, however, does not change the morbidity or mor-
tality in the critically ill [5].
Hypoalbuminaemia may result from the following: trans-
capillary leak; decreased synthesis; large volume body
fluid losses; and dilution due to fluid resuscitation.
The use of albumin for the treatment of hypovolaemia is
centred around the argument that albumin will remain in
the intravascular space. In the critically ill there is often an
inflammatory response that results in capillary leakage and
loss of protein (including albumin), inflammatory cells and
large volumes of fluid into the interstitial space.
The increased vascular permeability is a major cause of
hypoalbuminaemia in disease and injury [15–17]. In a
healthy adult albumin is drained by the lymphatics. In illness
albumin in the interstitium draws fluid into this space,
impairing re-expansion of the intravascular space and
increasing tissue oedema [18]. This could result in tissue
hypoxia, which may be a contributory cause of multiorgan
failure [19,20]. In critically ill patients hypoalbuminaemia is
a reflection of the severity of the underlying disease.
The rate of albumin synthesis is also significantly
decreased in the critically ill. The acute-phase response to
trauma, inflammation or sepsis results in an increase in the
gene transcription rates for the positive acute-phase pro-
teins such as C-reactive protein, and a decrease in the
rates of albumin mRNA transcription and thus synthesis
[21,22]. A sustained inflammatory response in critical
illness may lead to prolonged inhibition of albumin synthe-
sis. Interleukin-6 and tumour necrosis factor-a both act to
reduce gene transcription [23,24]. Inflammation, induced
by turpentine, in rats decreased the albumin mRNA con-
centration and synthetic rate, which reached a minimum
by about 36 h and then began to increase again [25,26].
Analbuminaemia
There are some healthy humans who are analbuminaemic
(essentially total lack of albumin). They have less than 1g/l
albumin in their circulation. They have a surprising paucity
of symptoms, possibly because increases in other con-
stituents of plasma such as globulins and lipids counter
the lack of albumin. The half-life of the small amount of
albumin present increases from 19 days to between 38
and 115 days [9].
Problems associated with albumin
administration
There are several potential problems associated with the
administration of this substance, and are discussed below.
Blood products
The use of any blood product is potentially harmful.
Although HAS is pasteurized to reduce the risk of infec-
tion, human immunodeficiency virus contamination of a
pooled source can be missed at the time of screening.
This is because of the window period of seroconversion in
donors who have these diseases. It has been suggested
[27–29] that estimates of the risk of plasma being
sourced from such a pool within the USA vary from one in
five pools for hepatitis B virus, to one in 39 for human
immunodeficiency virus, although this risk is being
reduced with improved testing. Interestingly, the pool from
which albumin is sourced for use in UK is from the USA.
This change in source of albumin occurred after the suspi-
cion that UK blood products are potentially contaminated
with prion proteins.
Biological products are not pure. They contain constituents
other than what is on the label. Albumin solution is allowed
to be green because of its bilirubin content. There are large
differences in the quality of albumin preparations. The pres-
ence of oligomers/polymers, endotoxins, haem com-
pounds, prekallikrein, bradykinin and other albumin-bound
proteins could alter the quality of albumin, and even result
in anaphylaxis. Up to 10% of albumin solutions may be
constituted by high-molecular-weight substances. This
means that 1g polymers/aggregates can be infused in a
patient receiving 50ml of 20% albumin [30,31].
Correction of hypovolaemia and fluid overload
Albumin continues to be used in hypovolaemia by its pro-
ponents. One advantage of hypertonic albumin is said to
be its ability to increase the intravascular volume by
drawing in interstitial fluid from the extravascular compart-
ment. This is limited, however, because in most critically ill
patients there is an increased capillary leakage and
extravasation of albumin into the interstitium [15–17].
For volume therapy in critically ill patients, no benefit over
other colloidal therapies has been shown. Stockwell et al
[32] examined 475 critically ill patients who were ran-
domly allocated to receive either 4.5% HAS or 3.5%
polygeline (Haemaccel, Hoechst UK) for intravenous
volume replacement during their stay in the intensive care
unit. There was no difference between the groups in thehttp://ccforum.com/content/4/3/151
incidence of pulmonary oedema or acute renal failure. That
study showed no benefit in outcome for patients treated
with albumin.
With rapid administration of albumin there is up to a four-
fold increase in volume retention, which can result in fluid
overload, especially pulmonary oedema. Maintenance of
the plasma oncotic pressure by albumin blunts the natri-
uretic response to sodium loading. Infusion of albumin
also results in water and sodium retention, which is
described below.
Pulmonary compromise
An increase in extravascular lung water is seen after lung
contusion, sepsis and cardiac failure. The pulmonary lym-
phatics have a limited ability to remove large volumes of fluid
from the interstitium, making it more vulnerable to oedema
than other tissues. Evidence [33] suggests that the pul-
monary dysfunction in critically ill, septic patients is indepen-
dent of colloid osmotic pressure. Change in pulmonary
capillary permeability is thought to be the primary determi-
nant of interstitial fluid accumulation in the lung after trauma
[8]. Leaking of albumin into the interstitium increases the
colloid oncotic pressure in this space, and may worsen con-
ditions, such as acute respiratory distress syndrome.
The detrimental effects of albumin on the lung may be
related to several factors, including hypervolaemia sec-
ondary to antinatriuresis and antidiuresis, and reversed
oncotic pressure secondary to increased extravascular
pulmonary albumin. Patients treated with albumin for
severe hypovolaemia were shown [19] to have a greater
dependence on respiratory support, and higher fraction of
inspired oxygen:arterial oxygen tension ratios compared
with the group who were not treated with albumin.
There is a potential for harm from the accumulation of
albumin macroaggregates in the interstitium of the lung,
especially among patients with smoke injury. Patients
treated with colloids for burns have a greater lung water
retention, at day 7 after injury [34].
Albumin and the microcirculation
Boldt et al [35] examined cardiorespiratory and circulatory
variables in critically ill patients treated with either human
albumin or hydroxyethyl starch (HES). There was no signifi-
cant difference between the two groups in the haemody-
namic variables studied, although cardiac index was higher
in the HES group. Long-term infusion of HES compared
with albumin produced improved systemic haemodynamic
variables, and specifically improved splanchnic perfusion.
Those investigators also investigated the effects of both
volume therapies on plasma concentrations of markers for
the inflammatory response [36]. They measured plasma
concentrations of adhesion molecules, which are signifi-
cantly increased during sepsis and indicate endothelial
activation or damage. They found that concentrations of
adhesion molecules were unchanged or decreased in
patients on long-term HES therapy, but in the albumin-
treated group concentrations were increased. This sug-
gests that the inflammatory process continued or
worsened in patients treated with albumin, whereas
patients given HES got better, possibly because of
improved microcirculatory haemodynamics.
Renal impairment
Albumin causes plasma expansion and increases renal
plasma flow, but paradoxically decreases glomerular filtra-
tion rate [37]. The mechanism for this decrease in
glomerular filtration rate is also unknown. A possible
mechanism is the decrease in clearance of albumin poly-
mers as a result of already impaired renal function seen in
serious illness. More specifically, albumin macroaggre-
gates could impede glomerular filtration. In addition, the
infusion of albumin can result in impaired sodium and
water excretion, and worsen renal failure. A proposed
mechanism is that albumin increases the oncotic pressure
within the peritubular vessels, causing a decrease in
sodium and water excretion [38,39].
Albumin was thought to increase the diuretic effect of
frusemide. Akcicek et al [40] showed that albumin does
not potentiate the natriuresis of frusemide. Albumin is
thought to bind to frusemide in the renal tubule, inactivat-
ing it. Because this is the site of action of frusemide, there
is a reduction in its diuretic effect [40].
Immune system
Adverse effects such as urticaria, fever and chills can
occur with albumin administration, suggesting an immune
response [8]. The transfusion of allogeneic blood or blood
products results in substantial and clinically significant
changes in recipient immune function. Although the main
problem is transfusion of white blood cells, large pools of
allogeneic albumin could affect host immunity [41,42].
Albumin therapy lowers the concentration of immunoglob-
ulins in the blood and causes a reduced response to
tetanus toxoid [43]. More studies need to be done to look
into recipient immune response after fluid transfusion.
Haemostasis
Albumin affects blood coagulation. This was noted
because there was a negative correlation between
albumin concentrations and heparin requirements in
patients undergoing haemodialysis. It seems to exert a
heparin-like action, perhaps related to a similarity in struc-
ture of the two molecules. Heparin has negatively charged
sulphate groups that bind to positively charged groups on
antithrombin III, thus exerting an anticoagulant effect.
Serum albumin has many negatively charged groups.Albumin enhances the neutralization of factor Xa by
antithrombin III.
The hypercoagulable state seen in the nephrotic syn-
drome may, in part, be explained by the accompanying
hypoalbuminaemia. This may also be related to the lack of
the inhibitory effect of albumin on platelet aggregation.
Such an inhibitory effect is both dependent on, and inde-
pendent of the cyclo-oxygenase system [44].
Drug elimination
The structure of the albumin molecule is such that it can
incorporate many different substances. It is a flexible mole-
cule, and bound compounds can be buried within the
structure. Many drugs, hormones and metals are bound to
albumin in the intravascular compartment. This binding is
potentially useful in the intravascular compartment. In
patients who are hypoalbuminaemic, excess toxicity of
highly albumin-bound drugs is known to occur. With
extravasation of albumin into tissue this function of
albumin binding could upset the concentration of these
substances at their effector sites, affecting their function
and possibly enhancing toxicity and contributing to mortal-
ity [45–47].
Increased mortality (Cochrane database)
In a meta-analysis of published trials the Cochrane collab-
orative group has shown that there is no clinical benefit for
albumin in the critically ill. They also show evidence that
the risk of death in patients given albumin was 6% higher
than that with other colloids [5].
Cost
Albumin is an expensive product. Compared with a 4%
gelatin solution, a 500ml bottle of 4.5% albumin costs up
to 10 times as much. Considering the amount of plasma
expanders required in critically ill patients, the use of
albumin represents a significant cost. Significant financial
benefit without clinical risk has been shown [48] by using
a protocol in which crystalloids are the primary agent of
choice in haemodialysis-induced hypotension. The use of
albumin has declined in the UK primarily because of its
expense and the availability of other colloids that are
equally effective [49]. As a result of the decline in albumin
use, the plasma products industry has launched a £1.4
million international programme to promote albumin,
despite official advice to restrict its use [50,51].
Guidelines from expert committees
The albumin expert working party for the Committee on
Safety of Medicines in the UK looked at the individual trials
in the Cochrane report that compared colloids with crys-
talloids, and concluded that the weighted relative risks for
mortality in these trials were as follows: 1.43 for albumin
versus crystalloids; 1.26 for dextrans versus crystalloids;
and 0.96 for other colloids versus crystalloids [52]. They
warn that special care is needed in illnesses that may
affect the capillary integrity. They also state that the mech-
anism of death with albumin might be fluid overload.
Because the inflammatory response is common in most
causes of critical illness, and this causes capillary leaki-
ness, their recommendation would suggest that it should
be avoided.
The therapeutic indications allowed by the Committee on
Safety of Medicines for 4.5% albumin include restoration
and maintenance of circulating blood volume where
volume deficiency has been shown and use of colloids is
appropriate. For 20% albumin this should include where
electrolyte or fluid load is contraindicated.
A Consortium of hospitals in the USA has also issued
guidelines for fluid resuscitation in haemorrhagic and non-
haemorrhagic shock, hepatic resection, cardiac surgery
and thermal injury [53]. They suggest stringent restrictions
for the use of albumin in these situations, crystalloids
being the fluids of choice. They also suggest that albumin
should be avoided in the event of cerebral ischaemia, and
nutritional intervention to correct hypoalbuminaemia. 
Conclusion
The use of albumin in the critically ill patient is not sup-
ported by scientific evidence. It is no more effective than
other agents used in the treatment of hypovolaemia. It has
detrimental systemic effects in the critically ill patient. Fur-
thermore, treatment of hypoalbuminaemia has no signifi-
cant benefit. Efforts should be concentrated on correcting
the underlying cause of disease to reverse hypoalbu-
minaemia. The use of albumin may cause death.
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